REZOLUTE, INC. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
REZOLUTE, INC. (RZLT) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $27.10 million as of 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2026-09-24
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $27.10M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $18.70M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $27.10M 10-K · filed 2026-09-24 |
| 2025-06-30 | $18.70M 10-K · filed 2025-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |